#AbbVie's long-acting anti-IL-13 antibody #zumilokibart – the main asset in its $10.9 billion takeover of Apogee Therapeutics – has hit the mark in a phase 2b trial in #atopicdermatitis, its lead indication.

pharmaphorum.com/news/apogee-...

PlaneAlert ICAO: A70E5B
Owner: ABBVIE
Flt: N554AV GA6C
Time: 2026-09-30 13:01:21 CEST
Min Alt: 32475 ft
Squawk: 0125
aircraft over heerlen - adsb planefence by kx1t - sdr-e airplanes flightaware faa

PlaneAlert ICAO: A70E5B
Owner: ABBVIE
Flt: N554AV GA6C
Time: 2026-09-30 12:58:41 CEST
Min Alt: 8742 m

adsb planefence planealert by kx1t - sdr-e adsbexchange flightaware faa

AbbVie Unveils Promising Phase 1 Results for Innovative Obesity Treatment at EASD 2026 #United_States #AbbVie #North_Chicago #ABBV-295 #EASD_2026

AbbVie Presents Promising Phase 2 Results for Zumilokibart at EADV 2026 as a Late Breaker #United_States #AbbVie #North_Chicago #Zumilokibart #EADV

AbbVie Presents Groundbreaking Dermatology Research Results at 2026 EADV Congress #United_States #dermatology #AbbVie #North_Chicago #EADV2026

Ferie illimitate, chief happiness officer e Team Camp: 5 pratiche con cui le aziende affrontano salute mentale e #burnout #abbvie #accenture #bending-spoons #benessere-aziendale #ferie-illimitate #great-place-to-work #hilti #lavoro #prestiter #salute-mentale

AbbVie Secures Rare Disease Drug Designation for Upadacitinib in Hidradenitis Suppurativa #Japan #AbbVie #Minato-ku #Hidradenitis_Suppurativa #Upadacitinib

New breakthrough: #AbbVie's tavapadon wins FDA approval for Parkinson’s.

The drug offers a new approach to treating motor symptoms linked to the condition.

Learn more: www.emjreviews.com/emj-gold/new...

Pharmalot.. Pharmalittle.. Good Morning: We’re reading about GLP-1s becoming lifestyle drugs, a setback for Merck and Daiichi, and more news.. statnews.com/pharmalot/20... #pharma #GLP #weight #obesity #cancer #patent #India #Merck #Roche #flu #pandemic #AbbVie #Novo #UK #Trump

The first product from #AbbVie's $8.7 billion takeover of #Cerevel two years ago – #Parkinsonsdisease therapy #tavapadon – has been approved by the #FDA.

pharmaphorum.com/news/abbvies...

PlaneAlert ICAO: A70E5B
Owner: ABBVIE
Flt: N554AV GA6C
Time: 2026-09-28 09:52:52 CEST
Min Alt: 35900 ft
Squawk: 4614
aircraft over heerlen - adsb planefence by kx1t - sdr-e airplanes flightaware faa

PlaneAlert ICAO: A70E5B
Owner: ABBVIE
Flt: N554AV GA6C
Time: 2026-09-28 09:32:43 CEST
Min Alt: 13707 m
Squawk: 4614
adsb planefence planealert by kx1t - sdr-e adsbexchange flightaware faa

AbbVie's Entenamig Shows Promising Results for Relapsed/Refractory Multiple Myeloma in Phase 3 CERVINO Trial #United_States #AbbVie #North_Chicago #Entenamig #CERVINO

BIOTECH · FDA approves AbbVie's once-daily Parkinson's pill, Juvmo

Tavapadon gives Parkinson's patients a new daily pill, built from AbbVie's $8.7 billion Cerevel deal.

Read the full story →

#Biotech #AbbVie #TheDailyFathom

#AbbVie #billion #disease #FDA #Parkinson #Parkinson's disease
🌐 www.newsmart.ch

#IambicTherapeutics, which specialises in applying #AI to #drugdiscovery and development, has filed for an #IPO on the #Nasdaq, shortly after adding #AbbVie to its roster of #pharma partners and launching the latest version of its #Enchant platform.

pharmaphorum.com/news/iambic-...

AbbVie Secures EU Approval for RINVOQ to Treat Active Polyarticular Juvenile Idiopathic Arthritis in Children #None #AbbVie #RINVOQ #Juvenile_Arthritis

AbbVie and Iambic Forge Groundbreaking Collaboration in AI-driven Drug Discovery #United_States #AI_Technology #AbbVie #North_Chicago #Iambic

AbbVie Unveils Real-World Effectiveness Data for VRAYLAR at Psych Congress 2026 #United_States #New_Orleans #AbbVie #Psych_Congress #VRAYLAR